WEDNESDAY, MAY 6, 2009 |
 Printable Version |
|
18.30 – 21.00 Opening
Ceremony |
||
| Musical Introduction | ||
| Welcome and Introduction | Nicholas C. Zoumbos Chairman, 10th International Symposium John M. Bennett Chairman, MDS Foundation |
|
| Suzanne Fleischman Memorial Lecture - Symptom and Treatment Burden: Effect on Quality of Life |
David Cella | |
| Asclepius Temples in Peloponnese | M. Petropoulos Archaeologist |
|
| Folk Dancing | ||
| Reception at the Congress Center | ||
|
||
| 8.30 – 9.50 Pathogenesis I: Immunopathogenesis in MDS |
Ghulam J. Mufti Chairman |
|
| MDS. An Immune Disorder? | Ghulam J. Mufti | |
| Diagnosis of Immune Pathophysiology in Patients with Low-risk MDS |
Shinji Nakao | |
| Controlling the “Fate” of T Cells in MDS | PK Epling-Burnette | |
| Telomere Biology and the Pathogenesis of clonal Evolution from Bone Marrow Failure |
Neal Young | |
|
||
| 9.50 – 11.10 Pathogenesis II: Molecular Pathogenesis in MDS |
Neal Young Chairman |
|
| BMI-1 and AML-1 Point Mutation in the Pathogenesis of MDS |
Akiro Kimura | |
| Molecular Changes as Detected by High-throughput Genomic Techniques in MDS |
Wolf-Karsten Hofmann | |
| Gene Expression Profiling in Patients with Myelodysplastic Syndromes, including patients with the Del(5q) |
Jacqueline Boultwood | |
| Clinical and Pathogenetic Implications of Array-based Karyotyping in MDS |
Jaroslaw P. Maciejewski | |
|
||
| 11.10 – 11.30 Coffee Break | ||
|
||
| 11.30 – 12.30 Diagnosis and Prognosis I | Peter L. Greenberg Chairman |
|
| Myelodysplastic Syndromes: Update on Classification | John M. Bennett | |
| Real-time Prognostic Evaluation in MDS | Luca Malcovati | |
| Updated Cytogenetic Risk Features in MDS - Present State |
Detlef Haase | |
| Update of Cytogenetic Risk Factors in MDS (Part II): A Strategy to Incorporate Fluorescence in situ Hybridization (FISH) and “FISH on a Chip” (aCGH) Results in Future Clinical Trials for the Myelodysplastic Syndromes (MDS) |
Marilyn L. Slovak | |
|
||
| 12.30 – 14.00 Morphology Workshop (Lunch/Poster Session) | John M. Bennett Jean Goasguen |
|
| The interactive morphology workshop will be conducted during lunch and will be open to the first 300 in a separate luncheon session |
||
|
||
| 14.00 – 15.00 Diagnosis and Prognosis II | Denise Wells Chairman |
|
| Disruption of Precise Gene Product Expression in Myelodysplasia |
Michael Loken | |
| Identification of Prognostic Subgroups by Flow Cytometry in Myelodysplastic Syndromes |
Arjan A. van de Loosdrecht | |
| Abnormalities Allow Distinction between Normal/Reactive and MDS Bone Marrow: How to Make it Easier? |
Alberto Orfao | |
|
||
| 15.00 – 16.30 Challenging the Experts: Case Studies | Moshe Mittelman Constantinos Tsatalas Co-Chairmen |
|
| Expert Panel: Drs. John Bennett, Pierre Fenaux, Peter Greenberg, Eva Hellström-Lindberg, Moshe Mittelman, Ghulam Mufti, Lewis Silverman, Guillermo Sanz, and Constantinos Tsatalas |
||
|
||
| 16.30 – 16.50 Coffee Break | ||
|
||
| 16.50 – 19.20 Simultaneous Sessions: | ||
| Session I: Diagnosis and Prognosis | Guillermo F. Sanz Michael Voulgareis Co-chairmen |
|
| Session II: Molecular Mechanisms and Pathophysiology | Jens Pedersen Bjergaard Constantina Sambani Co-chairmen |
|
|
||
| 16.50 – 18.50 Nursing Education Program: | ||
| Session I: Understanding MDS: Disease Overview | Argiris Symeonidis Kathy Heptinstall Co-Chairmen |
|
|
||
| 20.30 Faculty Dinner | ||
| FRIDAY, MAY 8, 2009 |
||
| 8.30 – 10.10 Overlap and Borderline States | Mario Cazzola Chairman |
|
| Myelodysplastic Syndromes with Unilineage Cytopenia (Neutropenia/Thrombocytopenia) |
Helen Papadaki | |
| Myelodysplastic Syndromes with Marrow Fibrosis | Matteo Giovanni Della Porta |
|
| Chronic Myelomonocytic Leukemia | David Bowen | |
| Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis |
Mario Cazzola | |
| Juvenile Myelomonocytic Leukemia | Christian Flotho | |
|
||
| 9.30 – 14.00 Patient and Family Forum | Argiris Symeonidis Kathy Heptinstall Co-Chairman |
|
|
||
| 10.10 – 11.10 Low-grade MDS and Marrow Failure States | Charlotte M. Niemeyer Chairman |
|
| Refractory Cytopenia of Childhood: Separating AA and Inherited Bone Marrow Failure Disorders – Results of Therapy |
Charlotte M. Niemeyer | |
| Inherited Syndromes and Low-risk MDS: Lessons Learned from the Greek Pediatric MDS Registry |
Sophia Polychronopoulou | |
| PNH: New Options | Anita Hill | |
|
||
| 11.10 – 11.20 Coffee Break | ||
|
||
| 11.20 – 12.40 Chelation Therapy: Issues and Answers | Alexandra Kouraklis-Symeonidis Chairman |
|
| The Basics: Iron Overload | Chaim Hershko | |
| Prospective Studies in Chelation Therapy | Christian Rose | |
| Assessing the Guidelines on Iron Chelation in MDS: Where are We? |
Norbert Gatterman | |
| Iron Toxicity and Chelation Therapy in Allogenic SCT | Theo de Witte | |
|
||
| 12.40 – 13.40 Lunch and Poster Viewing | ||
|
||
| 13.40 – 15.30 Optimizing Epigenetic Therapies
Issues and Strategies |
Michael Lübbert Chairman |
|
| In Vitro Basis for Treatment with Hypomethylating Agents and HDAC Inhibitors: Can Epigenetic Changes be Used to Monitor Treatment? |
Steven D. Gore | |
| Review of Trials with Azacytidine in Higher-risk MDS | Pierre Fenaux | |
| Decitabine in the Treatment of Higher-risk MDS | David Steensma | |
| Hypomethylating Agents in MDS Changing the Inevitable: The Value of Maintenance Therapy, Effects on Transfusions and Combination with Other Agents |
Lewis Silverman | |
| Hypomethylating Agents in Lower-risk MDS | Valeria Santini | |
|
||
| 15.30 – 16.15 New Agents in MDS | Pierre Fenaux Chairman |
|
| Should We Use Histone Deacetylase Inhibitors in the Treatment of MDS? |
Allen Yang | |
| Thrombopoietic Growth Factors | Mikkael Sekeres | |
|
||
| 16.15 – 16.45 Lecture: Innovative Clinical Trial Design in MDS | Elihu Estey | |
|
||
| 16.45 – 17.00 Coffee Break | ||
|
||
| 17.00 – 19.00 Simultaneous Sessions: | ||
| Session III: Molecular Mechanisms and Drug Targets | Theofanis Economopoulos Photis Beris Co-chairmen |
|
| Session IV: Therapy and Experimental Models | Valeria Santini Nikolaos Harhalakis Co-chairmen |
|
|
||
| 17.00 – 19.00 Nursing Education Program: | ||
| Session II: Case Presentations: Managing MDS Patients Effectively |
Erin P. Demakos, Phyllis Paterson Co-chairmen | |
|
||
| 20.30 GALA DINNER | ||
| SATURDAY, MAY 9, 2009 |
||
| 8.30 – 9.30 Risk-adapted Treatment Strategies and Novel Therapies |
Alan F. List Chairman |
|
| Low-risk MDS; Transfusion Therapy, Growth Factors and the European View on Lenalidomide |
Eva Hellström-Lindberg | |
| Management of Del (5q) MDS | Aristoteles Giagounidis | |
| Developmental Therapeutics for MDS | Alan List | |
|
||
| 9.30 – 9.45 Coffee Break | ||
|
||
| 9.45 – 11.00 Evolution in Transplantation in MDS | Theo de Witte Chairman |
|
| Allogeneic Stem Cell Transplantation in MDS: Reduced -intensity Conditioning and Donor Lymphocyte Infusion |
Nicholas Kröger | |
| New Preparatory Regimens: The Role of New Drugs | Michael Lübbert | |
| Reducing the Frequency of Relapse after Hematopoietic Cell Transplantation for MDS |
Joachim Deeg | |
| Reduced Intensity Regimens in Refractory Cytopenia |
Marco Zecca | |
|
||
| 11.00 – 12.30 Young Investigator’s Plenary Session and Tito Bastianello Award | Nicholas C. Zoumbos David Bowen Co-Chairmen |
|
|
||
| 12.30 Closing Remarks and Announcement of the 11th International Symposium on MDS |
Nicholas C. Zoumbos John M. Bennett David Bowen |
|
 |
|
     |
|